Pulmonary hypertension assessment and recognition of outcomes in scleroderma (PHAROS): Baseline characteristics and description of study population

Objective. Pulmonary arterial hypertension (PAH) increases mortality in systemic sclerosis (SSc). The multicenter PHAROS registry (Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma) prospectively follows subjects with SSc at high risk for or with incident pulmonary hypertension (PH). We describe the registry design and baseline characteristics of subjects enrolled during the first 18 months since the start of the study. Methods. High-risk subjects are enrolled and classified as Pre-PAH if they have (1) carbon monoxide diffusing capacity (DLCO) < 55% predicted; (2) percentage of predicted forced vital capacity/DLCO ratio ≥ 1.6; or (3) an estimated right ventricular systolic pressure > 35 mm Hg on echocardiography.Subjects with right heart catheterization (RHC)-confirmed incident PH (mean pulmonary artery pressure ≥ 25 mm Hg within previous 6 months) are subclassified into PAH, pulmonary venous hypertensionsecondary to left-side heart disease (PVH), and PH due to interstitial lung disease (PH-ILD).Baseline and biannual demographic, clinical, and laboratory data and patient-reported health questionnaires are collected.Results. There are 237 subjects enrolled in PHAROS. The majority are white (73%) and women (87%).There are 166 Pre-PAH and 71 Definite PH subjects (49 PAH, 7 PVH, and 15 PH-ILD).Conclusion. PHAROS is the largest US and Canadian cohort of subjects with SSc at high risk for orwith incident PAH. PAH-specific therapies are approved for 49/71 subjects with RHC-confirmed PAH. Analyses of PHAROS registry data will permit identification of risk factors for development of PAH among SSc patients at high risk for PAH and enhance understanding of the course of SSc-PAH. The Journal of Rheumatology